Toujeo Injection, Solution
Product Images NDC 0024-5869

Product Visual Gallery

This gallery contains 52 technical images submitted to the FDA as part of the official labeling for Toujeo (NDC 0024-5869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Toujeo 01)

Chemical structure diagram illustrating the amino acid sequence of insulin glargine, showing its A chain (21 amino acids) and B chain (31 amino acids) connected by disulfide bonds (S-S). Each amino acid is labeled in sequential order in two linear chains.*

FDA Label Image

Figure 1 (Toujeo 02)

A line graph showing the glucose infusion rate (GIR, mg/kg·min) over time (0 to 36 hours) after a subcutaneous injection of TOUJEO 0.4 units/kg. The GIR initially rises, remains relatively constant around 1 to 2 mg/kg·min for about 24 hours, and then gradually declines after 24 hours.*

FDA Label Image

Figure (Toujeo 03)

An anatomical illustration showing recommended subcutaneous injection sites for TOUJEO Max insulin glargine injection. The highlighted injection areas include the upper arms, stomach, and thighs on a human figure.*

FDA Label Image

Figure (Toujeo 04)

An instructional diagram of the TOUJEO Max insulin glargine 300 U/mL injection pen by Sanofi-Aventis U.S. LLC. It labels parts of the pen including the pen cap, cartridge holder, rubber seal, insulin scale, plunger, insulin name, dose window, dose pointer, dose selector, and injection button. A note clarifies that the plunger becomes visible only after several doses are injected.*

FDA Label Image

Figure (Toujeo 05)

The image shows a TOUJEO Max injection pen labeled for insulin glargine, a 300 Units/mL subcutaneous injection solution. The pen is branded by Sanofi-Aventis U.S. LLC and intended for once-daily use in diabetes management. The label highlights the proprietary name TOUJEO Max, dosage strength, and drug form clearly on the pen body.*

FDA Label Image

Figure (Toujeo 06)

TOUJEO Max 300 U/mL injection pen label showing lot number 123XY and expiration date 2029-10-31. The device features a barcode and a green end cap. Manufactured by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Figure (Toujeo 07)

An instructional illustration showing the operation of the TOUJEO Max insulin glargine injection pen. It depicts a hand holding the pen and pushing the injection button forward, with a blue arrow indicating the direction of the injection process.*

FDA Label Image

Figure (Toujeo 08)

An illustration showing a close-up side view of a green prefilled injection pen for TOUJEO Max (insulin glargine) 300 U/mL. The pen features a dosing window and a partially visible patterned label near the injection end.*

FDA Label Image

Figure (Toujeo 09)

An instructional illustration showing hands peeling back paper to reveal a green capsule or syringe barrel, demonstrating how to remove protective packaging or seal from the product prior to use.*

FDA Label Image

Figure (Toujeo 10)

An instructional illustration showing hands holding an insulin pen, likely demonstrating how to prepare or use the pen for injection. The image depicts grasping the pen and adjusting or removing a cap or outer part.*

FDA Label Image

Figure (Toujeo 11)

An instructional illustration showing a hand holding a TOUJEO Max insulin glargine injection pen, with another hand twisting off the pen cap. The image emphasizes the correct removal of the cap using a twisting motion indicated by blue arrows, and includes a red caution inset showing an improper cap removal method to avoid.*

FDA Label Image

Figure (Toujeo 12)

An instructional illustration showing the preparation of an insulin injection using a pen device. The image depicts a hand holding a pen injector filled with insulin glargine solution and another hand holding a small cap or needle cover, likely demonstrating needle attachment or removal steps for subcutaneous use.*

FDA Label Image

Figure (Toujeo 13)

An instructional illustration showing a hand holding the cap of a vial of TOUJEO Max (insulin glargine) 300 U/mL injection solution, with the cap being removed from the vial. Another hand is holding a syringe poised to withdraw the medication, demonstrating the preparation process for subcutaneous injection.*

FDA Label Image

Figure (Toujeo 14)

An instructional illustration showing a person holding a Toujeo Max insulin glargine injection pen. The image highlights the dose selector knob being turned to set the dose, with a close-up inset showing the dose window displaying the numbers 2 and 4.*

FDA Label Image

Figure (Toujeo 15)

An instructional illustration showing a hand holding an injection pen labeled TOUJEO Max insulin glargine 300 U/mL. A magnified view highlights a drop of liquid being expelled from the needle tip, indicating priming or removing air before injection.*

FDA Label Image

Figure (Toujeo 16)

The image shows a Toujeo Max SoloStar pen injector for insulin glargine injection, solution. The label indicates a strength of 300 Units/mL for subcutaneous use. The pen has a dose window and a dial mechanism, with instructions for single use per pen. It is labeled with the brand name Toujeo Max and is manufactured by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Figure (Toujeo 17)

An instructional illustration showing a person holding a TOUJEO Max insulin glargine injection pen. One hand grips the pen body while the other rotates the dose selector, indicated by a blue arrow, to set the prescribed dose. The pen label and dosing scale are partially visible.*

FDA Label Image

Figure (Toujeo 18)

A close-up image of a dosage dial showing the insulin unit setting with visible numbers 28, 30, and 32. This dial is part of an injection device for TOUJEO Max insulin glargine 300 U/mL subcutaneous solution by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Figure (Toujeo 19)

An illustration of a dose selector wheel from the TOUJEO Max insulin glargine injection pen, showing dose settings with numbers 28 and 30 visible in the window. The image focuses on the pen's dial used for adjusting the prescribed insulin dose.*

FDA Label Image

Figure (Toujeo 20)

An instructional illustration showing a person holding a TOUJEO Max insulin glargine injection pen for subcutaneous use, demonstrating how to insert the needle into the skin and administer the dose by pushing the plunger. The pen features a dose window and a dial for setting the insulin units.*

FDA Label Image

Figure (Toujeo 21)

An instructional illustration demonstrating the correct way to turn the dose knob on the TOUJEO Max insulin glargine injection pen. It shows the hand gripping the pen with an arrow indicating a counterclockwise turn and highlights a detailed view of the dose knob with a blue circle for correct action and a red circle indicating an incorrect method.*

FDA Label Image

Figure (Toujeo 22)

An instructional illustration showing how to hold and use a TOUJEO Max insulin glargine injection pen. It highlights holding the pen against the skin and pressing the dose knob, with a focus on the instruction to keep the pen pressed against the skin for 5 seconds after injection.*

FDA Label Image

Figure (Toujeo 23)

An instructional illustration showing a person holding a TOUJEO Max insulin glargine injection pen. The image depicts the removal of the pen cap by pulling it off, indicated by a blue arrow pointing away from the pen. The dosage window on the pen is visible with dose measurements marked up to 160 units.*

FDA Label Image

Figure (Toujeo 24)

An instructional diagram illustrating how to prepare or use an insulin pen injection. It shows hands holding the insulin pen with arrows indicating steps to turn or remove the cap, pointing to specific actions to take with the device.*

FDA Label Image

Figure (Toujeo 25)

An instructional illustration showing two hands opening a container. One hand holds a cap removed from the container, and the other hand is about to place or remove a small foil or plastic seal from the opening. The image likely demonstrates a step in the process of preparing or opening a medication container.*

FDA Label Image

Figure (Toujeo 26)

An instructional diagram showing hands detaching the cap from a TOUJEO Max insulin glargine injection pen. The image illustrates the correct way to remove the pen cap with a leftward arrow indicating the direction.*

FDA Label Image

Figure (Toujeo 27)

An illustration showing recommended subcutaneous injection sites on a human figure for insulin administration. Highlighted areas include the upper arms, stomach, and thighs, indicating typical locations for subcutaneous injections such as insulin glargine (TOUJEO Max).*

FDA Label Image

Figure (Toujeo 28)

An illustrated diagram of the TOUJEO Max SoloStar insulin pen showing labeled parts including the pen cap, cartridge holder with rubber seal, insulin scale, plunger, dose window, dose pointer, dose selector, and injection button. The pen is designed for subcutaneous injection of insulin glargine at 300 units/mL.*

FDA Label Image

Figure (Toujeo 29)

The image shows a TOUJEO Max SoloStar insulin glargine injection pen labeled for subcutaneous use at a strength of 300 units per milliliter (U/mL). The pen is marked for single patient use only and includes dosage adjustment instructions. The label features the Sanofi-Aventis U.S. LLC branding.*

FDA Label Image

Figure (Toujeo 30)

TOUJEO Max 300 U/mL injection, solution in a prefilled pen for subcutaneous use. The pen features a beige body with a green-striped label area and a white cap with a green top. Visible text includes a lot number and expiration date on the pen barrel. Manufactured by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Figure (Toujeo 31)

An instructional illustration showing hands holding a TOUJEO Max insulin glargine injection pen. The image depicts sliding the pen cover off the injection device, indicated by a blue arrow pointing to the right. This diagram demonstrates part of the preparation process for subcutaneous injection of the 300 U/mL insulin solution.*

FDA Label Image

Figure (Toujeo 32)

An illustration showing a portion of the TOUJEO Max insulin glargine injection pen, highlighting the dose window area. The diagram displays the dose indicator windows on the pen body, used for setting or reading the insulin dose for subcutaneous injection.*

FDA Label Image

Figure (Toujeo 33)

An instructional illustration showing hands holding a pen-type injection device, with one hand using a cloth to clean the threaded connection point of the device. This likely depicts part of the preparation steps before attaching a component or injecting a medication such as Toujeo Max insulin glargine injection.*

FDA Label Image

Figure (Toujeo 34)

An instructional illustration showing two hands preparing a medication cartridge by attaching a cap or protective cover to the top of the cartridge. The image focuses on the proper handling technique for assembly before injection.*

FDA Label Image

Figure (Toujeo 35)

An instructional diagram showing hands holding a TOUJEO Max insulin glargine injection pen. It depicts twisting off the pen cap and cautions against pulling the dose knob while removing the pen cap, indicated by a red arrow and prohibition symbol.*

FDA Label Image

Figure (Toujeo 36)

Illustration showing a hand holding a TOUJEO Max insulin glargine injection pen with dose markings visible, alongside another hand preparing a small vial or cartridge for use.*

FDA Label Image

Figure (Toujeo 37)

An instructional illustration showing a right hand removing a cap from a vial, with an insulin syringe held nearby. The syringe is marked for 300 units, indicating it is used for dosing insulin glargine injection, corresponding to TOUJEO Max 300 U/mL.*

FDA Label Image

Figure (Toujeo 38)

An instructional illustration showing a person adjusting the dose selector on a TOUJEO Max SoloStar insulin glargine injection pen. The close-up inset highlights the dose window indicating 4 units selected for subcutaneous injection.*

FDA Label Image

Figure (Toujeo 39)

An instructional diagram showing hands holding and operating an insulin pen injector labeled TOUJEO Max insulin glargine injection. The image illustrates the injection pen with a close-up of the needle releasing a spray, demonstrating how to prepare the injection for subcutaneous use.*

FDA Label Image

Figure (Toujeo 40)

TOUJEO Max SoloStar insulin glargine injection 300 Units/mL in a prefilled pen injector. The label shows dosage markings with units, product name with concentration, and a dosage adjustment indicator, designed for single patient use subcutaneous injection. The labeler is Sanofi-Aventis U.S. LLC.*

FDA Label Image

Figure (Toujeo 41)

An instructional illustration showing a hand gripping a TOUJEO Max SoloStar insulin glargine injection pen at 300 U/mL strength. The other hand is turning the dose selector with an arrow indicating the clockwise direction for adjusting the dose on the subcutaneous injection device.*

FDA Label Image

Figure (Toujeo 42)

An illustration showing the dose selection dial of an insulin pen injector. The visible numbers on the dial include 56, 60, and 64 units, with a triangular pointer indicating the selected dose.*

FDA Label Image

Figure (Toujeo 43)

Illustration of a close-up view of a dosage dial on a medical injection pen showing dose setting indicators between 56 and 60 units, related to subcutaneous insulin delivery.*

FDA Label Image

Figure (Toujeo 44)

An instructional illustration showing the use of the TOUJEO Max insulin glargine injection pen. The image depicts a hand holding the pen, with the needle inserted into skin, and an arrow indicating the direction for subcutaneous injection.*

FDA Label Image

Figure (Toujeo 45)

An instructional illustration showing the proper way to hold and adjust the dose on a TOUJEO Max insulin glargine injection pen. The image highlights turning the green dial on the pen's end to set the dose, with a close-up demonstrating the correct alignment of dose numbers. The incorrect method of gripping the dial from the side is marked with a red cross.*

FDA Label Image

Figure (Toujeo 46)

An instructional illustration showing the correct technique for administering an injection using the Toujeo Max injection pen. The image highlights holding the pen in place against the skin and pressing the injection button for 5 seconds to ensure full dose delivery.*

FDA Label Image

Figure (Toujeo 47)

An instructional diagram showing two hands handling a TOUJEO Max insulin glargine injection, solution 300 U/mL pen. The left hand holds the pen with a visible dosage window showing units from 100 to 900. The right hand is removing the pen cap with an arrow indicating the direction to pull the cap off. This illustrates preparing the subcutaneous injection pen for use.*

FDA Label Image

Figure (Toujeo 48)

Illustration showing how to adjust or operate an insulin pen injector, likely for TOUJEO Max (insulin glargine) 300 U/mL solution. It depicts fingers turning the dose selector knob on the pen and pressing the injection button, demonstrating the injection process with visible dose markings on the pen body.*

FDA Label Image

Figure (Toujeo 49)

Illustration showing hands opening a container and removing a vial or cartridge, depicting the preparation step for using an injectable solution.*

FDA Label Image

Figure (Toujeo 50)

Illustration showing hands preparing a Toujeo Max insulin glargine 300 U/mL injection pen by pulling off the pen cap. The image demonstrates proper handling of the subcutaneous injection device before use.*

FDA Label Image

Principal Display Panel (1.5 mL Pen Carton)

The packaging label for Toujeo SoloStar insulin glargine injection displays a 300 Units/mL (U-300) strength in a prefilled pen for subcutaneous injection. The label highlights single patient use, injection instructions, storage guidance, and cautions. Sanofi-Aventis U.S. LLC is identified as the labeler. The design features green dotted patterns and space for a security sticker.*

FDA Label Image

Principal Display Panel (3 mL Pen Carton)

Packaging label for Toujeo Max SoloStar insulin glargine injection 300 Units/mL (U-300) by Sanofi-Aventis U.S. LLC. It is a subcutaneous solution for injection provided as two prefilled pens, 900 units/3 mL each. The label includes storage instructions, usage warnings, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.